NEW YORK, NY / ACCESSWIRE / February 27, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Bright Health Group, Inc. (NYSE:BHG)
This lawsuit is on behalf of all persons and entities other than defendants that purchased or otherwise acquired: (a) Bright Health common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about June 24, 2021; and/or (b) Bright Health securities between June 24, 2021 and November 10, 2021.
Lead Plaintiff Deadline: March 7, 2022
The complaint alleges that during the class period Bright Health Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Bright Health had overstated its post-IPO business and financial prospects; (ii) the Company was ill-equipped to handle the impact of COVID-19-related costs; (iii) the Company was experiencing a decline in premium revenue because of a failure to capture risk adjustment on newly added lives; (iv) all the foregoing was reasonably likely to have a material negative impact on Bright Health's business and financial condition; and (v) as a result, the documents issued in connection with the IPO and Defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Learn about your recoverable losses in BHG: https://www.kleinstocklaw.com/pslra-1/bright-health-group-inc-loss-submission-form?id=24086&from=1
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: May 28, 2021 - November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
The FENC lawsuit alleges Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in FENC: https://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?id=24086&from=1
Gatos Silver, Inc. (NYSE:GATO)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive.
Lead Plaintiff Deadline: April 25, 2022
During the class period, Gatos Silver, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in GATO: https://www.kleinstocklaw.com/pslra-1/gatos-silver-inc-loss-submission-form?id=24086&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE : The Klein Law Firm